Women over 40 face hormonal shifts, sleep disruption, and body composition changes that affect how GLP-1 therapy is best deployed.
Hormonal context
Estrogen decline begins in perimenopause (typically late 30s through early 50s). Visceral adiposity tends to increase. Sleep quality often deteriorates. These are real headwinds for weight management.
What GLP-1 addresses
Visceral adiposity reduction. Glycemic improvement. Cardiometabolic risk reduction. Sleep apnea (especially with weight loss).
What it doesn't address
Hormonal symptoms (vasomotor, mood, vaginal). Bone density loss — work with your physician on calcium, vitamin D, and possibly DEXA.
Protein and resistance training
Higher relative importance than for younger patients. Target 1.6–2.0 g/kg protein. Resistance training 2–3×/week.
Pregnancy considerations
If pregnancy is a possibility, washout requirements apply (sema ≥2 months, tirz ≥1 month before conception). See drug interactions including the tirzepatide OCP interaction.